

Table 1. Clinical parameters.

	Value		Distribution		Source
Male proportion	0.87	Beta	$\alpha=52$	$\beta=8$	HETeCo trial*
% of laryngeal cancer (requiring CT instead of MRI)	0.22	Beta	$\alpha=13$	$\beta=47$	HETeCo trial*
% of patients receiving PET (arm B)	0.57	Beta	$\alpha=34$	$\beta=26$	HETeCo trial*
Recurrence risk over follow-up (5 years)	0.35	Beta	$\alpha=113$	$\beta=213$	[254]
% recurrences in the first 3 years	0.84	Beta	$\alpha=15.2$	$\beta=2.9$	[254]
Ratio surgery/re-irradiation	80:20	Beta	$\alpha=19.2$	$\beta=4.8$	Clinical opinion
Potentially curable relapses (A)	0.25	Beta	$\alpha=74.8$	$\beta=224.3$	Clinical opinion
Potentially curable relapses (B)	0.50	Beta	$\alpha=49.5$	$\beta=49.5$	Clinical opinion
Annual risk of second primaries (6 th year onwards)	0.03	Beta	$\alpha=97.0$	$\beta=3135.4$	[7, 254]
Potentially curable second primaries (6 th year onwards)	0.47	Beta	$\alpha=15$	$\beta=16$	[254]
% of patients receiving home-based palliative care	0.135	Beta	$\alpha=20,985$	$\beta=134,461$	[310]
% of patients admitted to the hospital in the last month of life	0.78	Beta	$\alpha=8,947$	$\beta=2,523$	[332]

* HETeCo trial preliminary data (n=60 patients). HETeCo: Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography.